Skip to main content
SpringerLink
Log in

Melanoma

  • Living reference work entry
  • First Online:
Braun-Falco´s Dermatology

  • 460 Accesses

Abstract

Melanoma is a malignant tumor that originates from the melanocytic cell system and predominantly occurs at the skin, but less frequently in the eye, meninges, and mucous membranes. Ultraviolet radiation is the most important exogenous risk factor and carcinogen in melanoma formation. Systemic melanoma progression is characterized by early lymphogenic and hematogenic metastasis. Advances in understanding the cell- and immunobiology of melanoma have led to effective mutation-based targeted and immunoncological therapies that provide a significant survival benefit for subgroups of patients, even at an advanced stage. However, melanoma remains responsible for about 90% of mortality from skin cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. (2009) J Clin Oncol 27(36):6199–206

    Google Scholar 

First Describer

  • Brenner S, Wolf R (1992) The “red face” – a warning sign of malignant melanoma? Acta Derm Venereol 72:464

    CAS  PubMed  Google Scholar 

  • Crowson AN, Magro CM, Mihm MC (1999) Malignant melanoma with prominent pigment synthesis: “animal type” melanoma – a clinical and histological study of six cases with a consideration of other melanocytic neoplasms with prominent pigment synthesis. Hum Pathol 30:543–550

    Article  CAS  PubMed  Google Scholar 

  • Dubreuilh MW (1912) De la mélanose circonscrite précancéreuse. Ann Dermatol Syphiligr (Paris) 3:129–230, 205–230

    Google Scholar 

  • Hutchinson J (1890) On senile moles and senile freckles and their relationship to cancerous processes. Arch Surg 2:218

    Google Scholar 

Further Literature

  • Balch CM, Cascinelli N (2006) Sentinel-node biopsy in melanoma. N Engl J Med 355:1370–1371

    Article  CAS  PubMed  Google Scholar 

  • Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Clark WH, From L, Bernardino EA et al (1969) The histogenesis of biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705–727

    PubMed  Google Scholar 

  • Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147

    Article  CAS  PubMed  Google Scholar 

  • Damage village D, Fisher DE, Garbe C et al (2015) Melanoma. Nat Rev Dis Primers 1:1–20

    Google Scholar 

  • Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  CAS  PubMed  Google Scholar 

  • de Almeida LS, Requena L, Rutten A et al (2008) Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am J Dermatopathol 30:207–215

    Article  PubMed  Google Scholar 

  • Dummer R, Ascierto PA, Gogas HJ et al (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315–1327

    Article  CAS  PubMed  Google Scholar 

  • Durnick A, Stolz W, Landthaler M et al (2004) Lentigo maligna and lentigo maligna melanoma in young adults. Dermatol Surg 30:813–816

    PubMed  Google Scholar 

  • Elder DE, Goldman LJ, Goldman SC et al (1980) Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 46:1787–1798

    Article  CAS  PubMed  Google Scholar 

  • Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N English J Med 363:809–819

    Article  CAS  Google Scholar 

  • Garrido M, Bastian B (2010) KIT as a therapeutic target in melanoma. J Invest Dermatol 130:20–27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472–492

    Article  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31(26):3182–3190. https://doi.org/10.1200/JCO.2012.47.7836. Epub 2013 Jun 1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492

    Article  CAS  PubMed  Google Scholar 

  • Hutchinson J (1857) Melanotic disease of the great toe following a whitlow of the nail. Transact Pathol Soc London 8:404–405

    Google Scholar 

  • Krown SE, Chapman PB (2004) Defining adequate surgery for primary melanoma. N Engl J Med 350:823–825

    Article  PubMed  Google Scholar 

  • Larkin J, Ascierto PA, Dreno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876

    Article  PubMed  Google Scholar 

  • Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767

    Article  PubMed  Google Scholar 

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.0, 2018, AWMF Registernummer: 032/024OL. http://www.leitlinienprogramm-onkologie.de/leit-linien/melanom/

  • Livingstone E, Schilling B, Zimmer L et al (2016) Drug therapy for metastatic malignant melanoma. Drug Ther 34:14–22

    Google Scholar 

  • Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444–451

    Article  CAS  PubMed  Google Scholar 

  • Miller AJ, Mihm MC (2006) Melanoma. N Engl J Med 355:51–65

    Article  CAS  PubMed  Google Scholar 

  • Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501

    Article  CAS  PubMed  Google Scholar 

  • Morton DL, Wen DR, Cochran AJ et al (1992) Management of early stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin N Am 1:247–259

    Article  Google Scholar 

  • Morton DL, Thompson JF, Cochran AJ et al (2006) Sentinel node biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1317

    Article  CAS  PubMed  Google Scholar 

  • Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D, German Dermatological Society, Dermatologic Cooperative Oncology Group (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11(Suppl 6):1–116, 1–126. https://doi.org/10.1111/ddg.12113_suppl. English, German

    Article  PubMed  Google Scholar 

  • Richardson SK, Tannous ZS, Mihm MC (2002) Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 47:77–90

    Article  PubMed  Google Scholar 

  • Roesch A, Burgdorf W, Stolz W et al (2006) Dermatoscopy of “dysplastic nevi”: a beacon in diagnostic darkness. Eur J Dermatol 16:479–493

    PubMed  Google Scholar 

  • Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma. Lancet 392(10151):971–984. https://doi.org/10.1016/S0140-6736(18)31559-9. Review

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergology, University Hospital Essen, Essen, Germany

    Alexander Roesch

  2. Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Carola Berking

Authors
  1. Alexander Roesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carola Berking
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Roesch .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Munich, Munich, Germany

    Gerd Plewig

  2. Department of Dermatology, University of Munich, Munich, Germany

    Lars French

  3. Department of Dermatology, University of Munich, Munich, Germany

    Thomas Ruzicka

  4. Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt, Germany

    Roland Kaufmann

  5. Clinic for Dermatology and Allergology, University of Marburg, Marburg, Germany

    Michael Hertl

Section Editor information

  1. Head of the Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt am Main, Germany

    Roland Kaufmann

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Germany, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Roesch, A., Berking, C. (2020). Melanoma. In: Plewig, G., French, L., Ruzicka, T., Kaufmann, R., Hertl, M. (eds) Braun-Falco´s Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58713-3_105-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-58713-3_105-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-58713-3

  • Online ISBN: 978-3-662-58713-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation